FDA Panel Votes Against Cephalon's Sparlon

A Food and Drug Administration advisory panel voted against recommending for approval Cephalon Inc.'s (CEPH) Sparlon treatment for attention deficit hyperactivity disorder. The stock price plummeted $9.51 to close at $63.80.